Evidence map›Paper›PMID 40832384›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Modelling Acral Melanoma in Admixed Brazilians Uncovers Genomic Drivers and Targetable Pathways.

Annie Cristhine Moraes Sousa-Squiavinato, Sara Santos Bernardes, Flávia C Aguiar, Antonio C Facciolo, Martín Del Castillo Velasco Herrera, J Rene C Wong-Ramirez, Patricia Basurto-Lozada, Aretha Brito Nobre, Geethanjali Annamalai, Rebecca Martins Cadimo do Nascimento and 20 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Annie Cristhine Moraes Sousa-SquiavinatoDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
Sara Santos BernardesTissue Microenvironment Laboratory, Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0001-6700-2447
Flávia C AguiarDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
Antonio C FaccioloDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
Martín Del Castillo Velasco HerreraWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
J Rene C Wong-RamirezResearch Program in Systems Oncology, University of Helsinki, Helsinki, 00100, Finland.
Patricia Basurto-LozadaLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, 76230, México.
Aretha Brito NobreDivision of Human Pathology, Brazilian National Cancer Institute, Rua Cordeiro da Graça, 156, Rio de Janeiro, 20220-400, Brazil.
Geethanjali AnnamalaiSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, USA.
Rebecca Martins Cadimo do NascimentoDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
Jacqueline BoccacinoWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Rafaela FagundesWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Pedro Sodré do R BarrosDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
Mariana de Moraes PitomboDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
Rebeca Olvera-LeónWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Larissa Satiko Alcantara Sekimoto MatsuyamaWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Jamie BillingtonWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Ian VermesWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Irving Simonin-WilmerLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, 76230, México.
Danielle G CarvalhoDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
João Pedro Cavalcante SimoesDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.
Priscila Valverde FernandesDivision of Human Pathology, Brazilian National Cancer Institute, Rua Cordeiro da Graça, 156, Rio de Janeiro, 20220-400, Brazil.
Luiz Fernando NunesHospital de Câncer II, Brazilian National Cancer Institute, Avenida Via Binário do Porto, 831, Rio de Janeiro, 20081-250, Brazil.ORCID 0000-0003-2835-6597
Andreia Cristina de MeloDivision of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.ORCID 0000-0002-1201-4333
Jadivan Leite de OliveiraHospital de Câncer II, Brazilian National Cancer Institute, Avenida Via Binário do Porto, 831, Rio de Janeiro, 20081-250, Brazil.ORCID 0000-0003-2035-9910
Meenhard HerlynMelanoma Research Center, Wistar Institute, Philadelphia, USA.ORCID 0000-0003-0839-0739
Andrew E AplinSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, USA.ORCID 0000-0002-2734-3244
Carla Daniela Robles-EspinozaLaboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro, 76230, México.ORCID 0000-0003-3277-7466
David J AdamsWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0001-9490-0306
Patricia A PossikDivision of Basic and Experimental Research, Brazilian National Cancer Institute, Rua Andre Cavalcanti 37, Rio de Janeiro, 20231-050, Brazil.ORCID 0000-0003-2899-0969

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Research Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Jessie Villanueva · 2017 to 2026
$13.9M
Targeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1M
Dissecting Phenotype Switching in Early Stage MelanomasR01CA259295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Meenhard F Herlyn, Markus Schober · 2022 to 2026
$3.1M
NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS R01 CA259295NCI NIH HHS U54 CA224070Wellcome Trust
6 · The paper itself

Abstract

Acral melanoma (AM) is an aggressive melanoma subtype with limited therapeutic options and poor outcomes. In non-European descent and admixed populations, like those residing in Latin America, AM accounts for a significant proportion of cutaneous melanoma cases. Here, we performed comprehensive genomic and functional profiling of AM from a uniquely diverse Brazilian cohort. Whole-exome and transcriptome sequencing revealed low mutation burden and predominance of copy number alterations, including high-amplitude focal amplifications termed hailstorms. These hailstorms frequently affected chromosomes 11, 5 and 22 and key oncogenes such as

Identifiers

PMID40832384
PMCPMC12363704

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.